You are here

The gut microbiome: A new weapon for immune regulation and treatment of type 1 diabetes

Description 
Our studies provide validation that the impact of dietary metabolites within the gut has local as well as far-reaching anti-inflammatory effects on host health. Taken together, these findings accentuate the powerful impact the triage of intestinal immune health, the gut microbiota and dietary factors have in the pathogenesis of various autoimmune and inflammatory diseases such as T1D, infections and IBD. Much effort has been made in recent years to uncover the exact mechanisms behind their effects on health and disease. We are advancing on sophisticated methods such as genomics, transcriptomics, proteomics, metabolomics and nutrition that allow us to understand how this dynamic trio works together. While more studies in humans are required, dietary SCFAs have shown to be promising novel therapeutics. Dietary SCFAs 'Nutrimetabolites' therapy may be specifically tailored and designed, alone or in combination with potential immunotherapies, to prevent or cure diseases, where the future of medicine lies.
Essential criteria: 
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords 
Nutrimetabolites, SCFAs, target immunotherapies, T1D
School 
Biomedicine Discovery Institute (School of Biomedical Sciences)
Available options 
PhD/Doctorate
Masters by research
Honours
BMedSc(Hons)
Time commitment 
Full-time
Physical location 
Clayton Campus

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.